Back to Top Skip to main content

DTRA contributes to historic Ebola vaccine effort

Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz) Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz)

Recommended Content:

Immunization Healthcare | Immunizations | Global Emerging Infections Surveillance | Global Health Engagement | Global Health Engagement

FORT BELVOIR, Va. — The team of researchers and program managers at the Defense Threat Reduction Agency (DTRA) that has worked to counter the threat of the Ebola Virus Disease (EVD) welcomed the announcement of the U.S. Food and Drug Administration’s (FDA) approval of the vaccine, Ervebo ®, to the pharmaceutical company Merck & Co., Inc., December 19, 2019.

The approval of the vaccine represents the culmination of nearly two decades of efforts by a host of teams from across the public and private sectors such as DTRA and Merck, international partners in North America, Europe and Africa, and non-governmental and international organizations. The World Health Organization (WHO) describes EVD as a rare but severe hemorrhagic fever. EVD has killed thousands over the course of outbreaks, primarily in sub-Saharan Africa, since it first appeared in the 1970s.

DTRA, a Department of Defense combat support agency that identifies and combats biological threats as part of its mission to counter weapons of mass destruction (WMD), began its work on the vaccine in 2014 during an especially deadly outbreak in West Africa. The outbreak made clear the danger EVD posed to U.S. national security interests abroad, as well as to the U.S. domestic population in the event of a pandemic. To counter the threat, DTRA quickly initiated a strategy to get a vaccine approved. The combat support agency coordinated a series of investment efforts and partnerships to deliver a baseline platform for a viable vaccine candidate to mitigate the spread of the deadly disease.

“DTRA’s agile contracting, and well-placed contacts throughout government, academia, and industry allowed DTRA to form partnerships and guide development of this vaccine from the early stages of development, through crucial preclinical, and critical phase 1 clinical safety trials to the actual phase 2 clinical efficacy trial that demonstrated effectiveness of this vaccine during the outbreak,” said L. Revell Phillips Ph.D., a member of DTRA’s research and development team.

DTRA’s pioneering approach started with a contract to BioProtection Systems, a small biotech company. DTRA and BioProtection Systems partnered with Public Health Agency Canada, who began developing the vaccine in 2001, to accelerate its development. With these three teams working together, the vaccine progressed to a series of nonclinical and clinical studies conducted at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) and Walter Reed Army Institute of Research (WRAIR) defense laboratories.

As the effort evolved, DTRA leveraged its USAMRIID partner’s research capacity, resulting in international partnering agreements with the WHO. DTRA also coordinated with teams across the U.S. government as development of the vaccine progressed. The efforts of this research and development consortium produced viable data that would be transitioned to next-level partners.

“We exercised our ability to develop partnerships for a relevant need, which was critical in transitioning medical countermeasures to our advanced developers at the speed of relevancy,” said Army Maj. Jeffrey Froude, DTRA’s program manager for the EVD Vaccine.

Froude explained that DTRA bolstered its research and development investments through two key U.S. governmental partners. First, DTRA worked closely with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, for advanced trials and manufacturing activities. Second, DTRA teamed with the DoD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for the task of immunoassay development. For that development effort, JPEO-CBRND’s, office of the Joint Program Manager for CBRN Medical took the lead.

Following several years of coordinated research and development efforts by the coalition of partners, the promising vaccine candidate transitioned to next-level partners BARDA and Merck for more advanced human clinical trials and product manufacturing of the EVD vaccine.

“This vaccine’s rapid progress is a testament to the power of partnerships among government agencies and with the private sector,” said BARDA director Rick Bright.

Next-level partner BARDA and Merck, served as the transition point to conduct more advanced human clinical trials and product manufacturing on the Ebola vaccine with the Joint Program Executive office (JPEO) providing a testing capability that allowed Merck to test human and non-human primate samples. The Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical (JPM-CBRN), Army Col. Ryan Eckmeier, stated that this “interagency partnership from the beginning was critical to advancing this vaccine product.”

Merck’s expertise with licensing and manufacturing was instrumental in advancing the vaccine. The pharmaceutical giant partnered with the WHO, United Nations International Children's Emergency Fund, and Gavi Vaccine Alliance, among others, to strategize on how to best implement future public health preparedness and response efforts against EVD.

“We share in this achievement, and thank you all personally for your amazing support over the last five years,” said Beth-Ann G. Coller, executive director of Merck’s vaccine team in a note to the DTRA team. “This has truly been a journey and one that we are proud to have shared with our colleagues in DoD. Without the early and continued support of DTRA we would not be here today.”

DTRA continues to leverage its successful partnerships as the agency works to develop future countermeasures. DTRA and BARDA have active partnering agreements to develop vaccine and therapeutic medical countermeasures to address a diverse range of viral and bacterial infectious disease threats. Efforts will use a similar model to the one that supported development and approval of the EVD vaccine.

“As DTRA moves forward to new challenges, we will leverage continued utilization of the Ebola vaccine model, using a diverse range of ways that we can work with our academic, international, interagency and industrial partners through grants, contracts and other transaction authorities,” said Froude. “We have a proven paradigm on how to efficiently advance medical countermeasures working with our U.S. government partners in these endeavors.”

Disclaimer: Re-published content may be edited for length and clarity. Read original post.

You also may be interested in...

Immunization Tool Kit 9th Edition

Publication
4/7/2021

A practical reference that facilitates and enhances the global delivery of quality immunization healthcare to Department of Defense (DoD) beneficiaries and employees. The Defense Health Agency Immunization Healthcare Division (DHA-IHD) publishes the Immunization Tool Kit based on national recommendations, evidenced-based, peer-reviewed published medical literature, and clinical practice guidelines.

Recommended Content:

Immunization Healthcare

Eight nations participate in West African virtual pandemic exercise

Article
3/24/2021
Picture of military personnel wearing a face mask looking at a laptop computer

Medical experts from six African nations, the United Kingdom and the United States, participated in a Virtual Pandemic Preparation and Response Engagement exercise.

Recommended Content:

COVID-19 Toolkit | Coronavirus | Global Health Engagement | Partners

Infant Immunization Week

Infographic
3/23/2021
Social media graphic for National Infant Immunization Week showing a service member holding a baby

Social media graphic for National Infant Immunization Week showing a service member holding a baby

Recommended Content:

April Toolkit | Immunization Healthcare

New Army surveillance program designed to keep service members safe

Article
3/10/2021
Military personnel wearing a face mask hanging a light in a tree

Collecting vector samples allows for PHC-P scientists to analyze areas of interest for potential vector-borne diseases that could impact the health of the force.

Recommended Content:

Public Health | Global Health Engagement | Bug-Borne Illnesses | Mosquito-Borne Illnesses

Trained military personnel ready to help with COVID-19 vaccinations

Article
2/23/2021
Military health personnel wearing a mask giving the COVID-19 vaccine to a man who is also wearing a face mask

Military prepped and ready to help with civilian COVID-19 mass vaccinations

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | Immunizations

Order of Military Medical Merit presented to USU medical student

Article
2/19/2021
Military personnel receiving the Order of Military Merit

Army 2nd becomes the first USU medical student to receive the Order of the Military Medical Merit.

Recommended Content:

Combat Support | Health Readiness | Global Health Engagement

Marines, Sailors with PHIBRON 11, 31st MEU receive COVID-19 vaccine

Article
2/19/2021
Military health personnel giving the COVID-19 Vaccine to military personnel

Vaccination for service members is voluntary, as vaccines are currently authorized for emergency use.

Recommended Content:

Coronavirus | Immunization Healthcare | COVID-19 Vaccine Efforts

USU cohort study investigates COVID-19 impacts on DOD personnel

Article
2/18/2021
Military health personnel wearing a mask and a face shield holding up a sign that has the number eighteen on it

USU is conducting a study to better understand the symptoms and course of COVID-19 disease and identify risk factors in the military population.

Recommended Content:

COVID-19 Toolkit | Immunizations | COVID-19 Vaccine Efforts | Coronavirus

Flu Vaccination Trends Among Military Beneficiaries (December 2020)

Report
1/26/2021

This issue brief explores time trends for flu vaccination rates among military health care beneficiaries.

Recommended Content:

Health Care Survey of DoD Beneficiaries | Immunization Healthcare | Immunization Tool Kit

Recommendations for Mass Immunization Events During Pandemic Conditions

Fact Sheet
12/28/2020

During pandemic conditions, planners of mass immunization events need to consider additional measures to minimize risk of COVID-19 or similar infectious disease transmission.

Recommended Content:

Immunization Healthcare

AFHSD’s GEIS collect data worldwide to support force protection

Article
12/22/2020
Medical personnel scanning forehead of soldier with thermometer

AFHSD/GEIS continue work with partners across the globe in their efforts to combat COVID-19 and protect military readiness.

Recommended Content:

Health Readiness | Public Health | Coronavirus | Biological Surveillance Tools | Global Health Engagement | Armed Forces Health Surveillance Branch | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

COVID-19 Vaccine Update | How Vaccines are Developed

Video
12/14/2020
COVID-19 Vaccine Update | How Vaccines are Developed

COVID-19 vaccines are within sight in the United States! Scientists continue making progress in testing and monitoring COVID-19 vaccines for safety and effectiveness, and the federal government is ensuring that all adults who want a vaccine will be able to get one at no cost. Learn how these and other vaccines are developed, tested, and authorized for use – and how they work to prevent diseases like COVID-19. This video uses interviews and visuals to help viewers understand the science behind vaccines and why there is reason for optimism. Experts featured in the video include: Dr. Anthony Fauci, National Institutes of Health; Dr, Moncef Slaoui, Operation Warp Speed; Dr. Stephen Hahn, Food and Drug Administration; Dr. Robert Kadlec, Assistant Secretary for Preparedness and Response in the Department of Health and Human Services. For more information, visit http://www.coronavirus.gov.

Recommended Content:

COVID-19 Vaccine Efforts | Immunization Healthcare | COVID-19 Vaccine Toolkit

Forging of civil-military anvil against COVID-19 focus at GHSA

Article
11/9/2020
U.S. and Thai soldiers stand together during a medical exercise.

“Defense partnerships around the world are key.”

Recommended Content:

Coronavirus | Global Health Engagement | Health Readiness | Global Health Engagement

BAMC, Argentine Army medical providers share COVID-19 best practices

Article
11/4/2020
Video teleconference image

U.S. Army South facilitated the virtual subject matter expert (SME) exchange between BAMC and CMMH.

Recommended Content:

Coronavirus | Global Health Engagement | Technology | COVID-19 Vaccine Efforts | Public Health | Convalescent Plasma Collection Program

MHS ensures vaccine safety with immunization health care specialists

Article
11/2/2020
Military personnel, wearing a mask, looking at a syringe and a vial.

Temperature plays a critical role in vaccine safety.

Recommended Content:

Immunization Healthcare | Vaccine Storage and Handling
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 12

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.